Mechanisms and Clinical Implications of Second-Generation Antipsychotics

Introduction to Second-Generation Antipsychotics

All second-generation antipsychotics share a fundamental mechanism: serotonin 5-HT2A receptor antagonism combined with dopamine D2 receptor antagonism or partial agonism, though each agent has a unique receptor binding profile that determines its clinical effects and side effect profile 1

Risperidone, Paliperidone, Olanzapine, Quetiapine, and Ziprasidone function primarily as serotonin-dopamine receptor antagonists with varying receptor affinities 1
Aripiprazole represents a mechanistically distinct class as a dopamine D2 partial agonist with significant 5-HT1A partial agonism and 5-HT2A antagonism, contributing to prefrontal dopaminergic activation 1
Clozapine has the most complex and atypical mechanism, with weak D2 receptor antagonism combined with potent 5-HT2 receptor inhibition, and efficacy likely stems from effects on multiple neurotransmitter systems beyond simple D2 blockade 2, 3

The American College of Cardiology recommends considering aripiprazole as first-line due to its superior metabolic profile 1
Treatment decisions must be based on specific receptor profiles and side effect vulnerabilities, not generational labels, and clozapine should be reserved for treatment-resistant cases after failure of at least two other antipsychotics 1, 3
Agents with high anticholinergic properties should be avoided in elderly or cognitively impaired patients 1

Highest metabolic risk is associated with clozapine and olanzapine, while aripiprazole, ziprasidone, lurasidone, asenapine, and iloperidone have the lowest metabolic risk 1
Before initiating any second-generation antipsychotic, measure BMI, waist circumference, blood pressure, HbA1c, glucose, lipids, prolactin, liver function, electrolytes, complete blood count, and EKG, with follow-up including glucose at 4 weeks, weekly BMI/waist/blood pressure for 6 weeks, then comprehensive metabolic panels at 3 months and annually 1

Never combine multiple QT-prolonging antipsychotics due to fatal arrhythmia risk 1
Second-generation antipsychotics as a class carry increased atrial fibrillation risk, with clozapine, olanzapine, and quetiapine showing highest risk 4

Full antagonism of D2 receptors in the nigrostriatal pathway leads to muscle rigidity and tremor, reflecting a higher risk of EPS with agents that are complete D2 blockers. 5
The distinction between full antagonism and partial agonism directly influences the side‑effect profile, increasing the likelihood of EPS (including akathisia) with full antagonists compared with partial agonists. 6

Lurasidone and aripiprazole both demonstrate more favorable metabolic effects than high‑risk antipsychotics such as clozapine and olanzapine, showing minimal weight gain and negligible impact on glucose or lipid parameters. 7

Full D2 antagonism in the tuberoinfundibular pathway causes a greater increase in prolactin levels with lurasidone, whereas partial agonism limits prolactin elevation. 8

Because neuroleptic malignant syndrome requires D2 antagonism, agents that are full D2 blockers carry a theoretical risk of NMS, whereas partial agonists have a lower associated risk. 5

All facts are supported by the cited references and presented in English with generic patient descriptors.